We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Roche NimbleGen and Affymetrix Expand Licensing Agreement
News

Roche NimbleGen and Affymetrix Expand Licensing Agreement

Roche NimbleGen and Affymetrix Expand Licensing Agreement
News

Roche NimbleGen and Affymetrix Expand Licensing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Roche NimbleGen and Affymetrix Expand Licensing Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Roche NimbleGen Inc., a company of Roche Applied Science, and Affymetrix Inc. announced that they have expanded the terms of the license to a number of Affymetrix patents originally granted in October 2006. The expanded license now provides certain diagnostic rights for array-based DNA copy number analysis and array-based re-sequencing in addition to covering the manufacture, use and sale of nucleic acid microarrays and related products and services in the research field. Financial details of the expanded license were not disclosed.

Roche NimbleGen is a leading innovator, manufacturer and supplier of a proprietary suite of DNA microarrays, consumables, instruments and services. Roche NimbleGen uniquely produces high-density arrays of long oligo probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. The improved performance is made possible by Roche NimbleGen’s proprietary Maskless Array Synthesis (MAS) technology, which uses digital light processing and rapid, high-yield photochemistry to synthesize long oligo, high-density DNA microarrays with extreme flexibility.

Advertisement